[61]Stein AS,Kantarjian H,G o kbuget N,et for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant,2019,25(8)::10.1016/

[62]Kantarjian HM,Deangelo DJ,Stelljes M,et ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia:Final report and long-term survival follow-up from the randomized,phase 3 INO-VATE study[J].Cancer,2019,125(14)::10.1002/cncr..

[63]Oshikawa G,Kakihana K,Saito M,et maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia[J].Br J Haematol,2015,169(5)::10.1111/bjh..

[64]Davids MS,Kim HT,Costello C,et al.A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation[J].Blood,2020,135(24)::10.1182/blood..

[65]Davids MS,Kim HT,Bachireddy P,et for Patients with Relapse after Allogeneic Transplantation[J].N Engl J Med,2016,375(2)::10.1056/NEJMoa.

[66]Ijaz A,Khan AY,Malik SU,et Risk ofGraft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation[J].Biol Blood Marrow Transplant,2019,25(1)::10.1016/

[67]Choi I,Yoon SR,Park SY,et natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation:a dose-escalation study[J].BiolBlood MarrowTransplant,2014,20(5)::10.1016/

[68]Ciurea SO,Schafer JR,Bassett R,et al.Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation[J].Blood,2017,130(16)::10.1182/blood-2017-05-.

[69]Wang D,Huang XF,Hong B,et of intracellular immune checkpoint-silenced DC vaccine[J].JCI Insight,2018,3(3):e.DOI:10.1172/.

[70]Merker M,Salzmann-Manrique E,Katzki V,et of HematologicMalignanciesby AllogeneicCytokine-Induced Killer Cell or Donor Lymphocyte Infusions[J].Biol Blood Marrow Transplant,2019,25(7)::10.1016/

[71]Comoli P,Basso S,Riva G,et T-cell therapy in Ph+ALL patients on tyrosine-kinase inhibitors[J].Blood,2017,129(5)::10.1182/blood-2016-07-.

[72]Chapuis AG,Egan DN,Bar M,et al.T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia rela pse post-transplant[J].NatMed,2019,25(7)::10.1038/s-019-0472-9.

（本文由浙江省医学会推荐）

文章来源：《中国实验血液学杂志》 网址: http://www.zgsyxyxzz.cn/qikandaodu/2021/0508/635.html